Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Only general labeling support for rare serious muscle injury and possible muscle-related symptoms is present. Several sleepiness/drowsiness related claims are not supported or not addressed in the provided label content, and one symptom-detail (tea-colored urine) is not substantiated.
Category Scores
Accurate Statements
Statins can rarely be associated with serious muscle injury.
Label 5.1: rare cases of rhabdomyolysis with acute renal failure reported with LIPITOR and other drugs in this class.
Some people can experience tiredness, weakness, or muscle-related symptoms on statins.
Label 5.1: myopathy defined as muscle aches or muscle weakness. Label 6.2: postmarketing adverse reactions include fatigue; also muscle-related adverse reactions are listed generally.
Severe muscle pain and marked weakness may indicate serious muscle injury associated with statins.
Label 5.1: patients should report unexplained muscle pain, tenderness, or weakness; therapy should be discontinued if myopathy is diagnosed or suspected.
Unsupported Statements
Sleepiness is not a commonly reported side effect of Lipitor (atorvastatin).
The provided label content does not explicitly state that sleepiness/drowsiness is not commonly reported. Table 2 lists common adverse reactions but the label also includes insomnia (Table 2) and fatigue (postmarketing), so the claim is not directly and unambiguously supported by the supplied label text.
In most people, Lipitor is not associated with drowsiness or sedation.
No provided label section states that drowsiness/sedation does not occur in most people.
Sleepiness is more often caused by other drugs than by statins.
No provided label content compares causality of sleepiness between atorvastatin and other drugs.
Contradictions
Important Omissions
Safety/monitoring information relevant to muscle symptoms (e.g., advice to report unexplained muscle pain/tenderness/weakness and discontinuation guidance) is only partially reflected in the claims (missing some label wording and management actions).
Importance:
Moderate
The claim includes 'dark or tea-colored urine' as a specific indicator, but the provided label text does not substantiate this specific symptom detail (it mentions myoglobinuria in the context of rhabdomyolysis rather than explicitly listing dark/tea-colored urine as a symptom patients should report).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Sleepiness/drowsiness assertions are not supported by the provided label content and could mislead interpretation of adverse effect profiles. The additional symptom detail ('tea-colored urine') is not substantiated by the supplied label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Claims about sleepiness/drowsiness (including comparative causality and 'not commonly reported'/'most people') are not supported by the provided FDA label text, and one symptom detail (tea-colored urine) is not explicitly supported.
Suggested Improvement
Limit claims to label-supported muscle injury information (e.g., muscle pain/tenderness/weakness and associated risk of rhabdomyolysis) and remove or qualify sleepiness/drowsiness statements unless the provided label text explicitly addresses them.